Houston Methodist Hospital is leading the way in the new expanded indication trial for the CoreValve Evolut R System, a minimally invasive treatment for aortic stenosis patients with failing aortic heart valves.
The first two trials focused on patients with an extreme and high surgical risk of mortality. The extreme trial showed that transcatheter aortic valve replacement (TAVR) was better than medical therapy and it was shown to be superior to open heart valve replacement in the high risk trial. The current trial, SurTAVI, found that TAVR was equally as effective as open surgery.
The SurTAVI results recently appeared in the New England Journal of Medicine and were presented at the 2017 American College of Cardiology (ACC) conference by Michael Reardon, M.D., a cardiovascular surgeon at Houston Methodist DeBakey Heart & Vascular Center and the national surgical principal investigator for the SurTAVI trial. Reardon will take on the same role for the new trial looking at low-risk patients.
“The low risk trial includes patients that have a less than 3 percent chance of mortality after open surgery and small chance that they will require an extended stay in the ICU or on a ventilator. This represents about 75 percent of patients. The standard treatment in such patients is open heart surgery to replace the valve,” Reardon said.
Aortic stenosis is a common heart problem caused by narrowing of the heart’s aortic valve due to excessive calcium deposited on the valve leaflets.
“When the valve narrows, it does not open properly, making the heart work harder to pump blood throughout the body,” said Neal Kleiman, M.D., an interventional cardiologist and the low-risk trial principal investigator for Houston Methodist Hospital. “Eventually, this causes the heart to weaken and function poorly, which may lead to heart failure and ultimately death.”
The CoreValve Evolut R System replaces a diseased aortic heart valve through a minimally invasive procedure, without surgical removal of the diseased valve. The device is typically inserted via an artery in the leg and then guided through the arteries into the heart. Once in place, the device expands and takes over the original valve’s function to enable oxygen-rich blood to flow efficiently out of the heart. The system also provides physicians with the option to recapture the valve and reposition it during the procedure as necessary.
The trial will recruit more than 1,200 low-risk patients from up to 80 clinical sites in the United States. It is designed as an adaptive trial with a primary endpoint of all-cause mortality or disabling stroke.
“All the patients in the trial are reviewed by a national committee and then they are randomly selected by a computer program to receive either this procedure or an open surgical aortic valve replacement,” Kleiman said. “One of the benefits for patients is that regardless of which treatment they receive, they are very closely monitored throughout the process. Their cases are reviewed by at least five experts.”
“The success of the previous trials has given a new lease on life to patients who otherwise would not have limited options to treat their aortic stenosis,” Reardon said. “We believe TAVR will be as effective in this group of low-risk patients as it was in the high and intermediate risk patients.”
The CoreValve Evolut R transcatheter valve and the CoreValve EnVeo R Delivery Catheter System were FDA-approved for commercial use in the United States in June 2015 for severe aortic stenosis patients who are at high or extreme risk for surgery.
For more information, or to enroll in this study, please call Houston Methodist Hospital at 713.441.3250.
Baby shower help for 50 Veteran mothers at Miami VA hospital https://t.co/gzMBOgxeit via @wsvn
RT @bilalmomhammad: Great to see our pathology colleagues at @utmbhealth doing so well !!! @utmbnews @UTMB_Pathology @UTMBProvost https://t…
MD Anderson Cancer Center@MDAndersonNews
Daughter, caregiver Carrick Terhune shares the creative ways she supported her mom through #protontherapy for a rare #headandneckcancer: https://t.co/MpKEHxoaQO @MDAProtons #hncsm #endcancer
Researchers from Baylor College of Medicine, @MethodistHosp and @TexasChildrens receive a Specialized Center of Research grant to expand blood cancer therapy options. https://t.co/IcGckHPSBM #grants #cancer #research
RT @BruceTjadenMD: Here at @UTCVSurgery and @UTHealth, we are carrying out a #randomized #ClinicalTrial to compare #medical management vs #…
Veteran Affairs Office in Des Moines, IA holding coat drive https://t.co/IUDLZBpiZF via @weareiowa5news
RT @MillionHeartsUS: #Stroke risk increases with age, but strokes can (and do) happen at any age. Raise awareness of the importance of stro…
RT @BCMHouston_News: We are pleased to welcome Dr. Alastair Thompson to @bcmhouston! Dr. Thompson will lead #breastcancer surgical oncology…
MD Anderson Cancer Center@MDAndersonNews
“We’re really hopeful that we can identify a group of women who can get a much bigger and longer response,” says our @JenniferLitton of #immunotherapy to treat #breastcancer. #endcancer https://t.co/vv1JYis5rl
RT @HRSonline: Sudden #cardiacarrest claims 1 life every 90 secs. A few #SCA risk factors include a previous #heartattack, family history o…
The Dallas, TX VA and Vet Center teams met last week with leadership from the Urban Inter-Tribal Center of Texas to outline how their respective organizations can join forces to effectively reach and serve American Indian and Alaska Native Veterans. https://t.co/EBX1x6cPoV
RT @RiceUGPS: Lots of positive change coming to campus: the university is studying ways to create safe pathways for cyclists, and has also…
TAMU Health Sciences@TAMHSC
The Good Run . . . #MilesforSmiles in its 10th yearOn Nov. 3, the @TAMUdental student-led Miles for Smiles continues its stride at Exall Park in Dallas with its 10th annual runathon. https://t.co/5PFPnaDnOL#TAMHSC #AggieHealth #TAMUHealth #Dentistry #DentalStudents #TAMU https://t.co/NJaxKMawVq
University of Houston@UHouston
The John O'Quinn Foundation donates $3.5M to the UH College of Medicine, UH researchers envision in-home rehab for stroke patients, and Valenti students produce a web cooking show — here are your 60-second highlights of what's happening at UH #UHMoment https://t.co/1ork3iw0kz
CHI St. Luke's Health@CHI_StLukes
Sometimes it’s difficult to sift through the rumors to get the facts about #BreastCancer. We’re debunking five common myths, and they just might surprise you: https://t.co/pMnncNr4ul https://t.co/0HNfCjQYgI